Case Caption: Rhode Island Laborers Health & Welfare Fund v. Bausch Health Companies Inc., et al.
Court: Rhode Island Laborers Health & Welfare Fund v. Bausch Health Companies Inc., et al.
Case Number: 1:25-cv-00479
Judge: Honorable Melissa R. DuBose
Plaintiff: Rhode Island Laborers Health & Welfare Fund
Defendant: Bausch Health Companies Inc., Bausch Health Ireland Ltd., Salix Pharmaceuticals, Ltd, Salix Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., Teva Pharmaceuticals USA, Inc., and Actavis Laboratories FL, Inc.
Class Period: September 22, 2021–Present
This antitrust case against brand drug company, Bausch, and generic drug company, Teva, concerns the drug Xifaxan (rifaximin), an oral antibiotic, which is used to treat Irritable Bowel Syndrome with Diarrhea (IBS-D), among other things. In particular, plaintiff alleges that Bausch and Teva entered into an unlawful reverse payment settlement and that Bausch fraudulently obtained patents and/or improperly submitted patents to the U.S. Food and Drug Administration in connection with its New Drug Application for Xifaxan, which have delayed the launch of a generic version of Xifaxan and limited generic competition, resulting in higher prices for third-party payors. The plaintiff filed an initial complaint on September 22, 2025 and an amended complaint on December 1, 2025.